Daiichi Sankyo Co. Ltd., of Tokyo, said the FDA approved Savaysa (edoxaban) tablets, a once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.